Company Served as Sponsor and Provided Operational Leadership for Study Conducted in Partnership with TGen and Virta HealthContinue reading
Author Archive: AZBio
NIH invests $150 million in human-based research to reduce use of animal models
New program will develop, validate and standardize research tools to develop more sophisticated and relevant models of disease. Continue reading
Arizona Chamber Foundation, ACA Release ArizonaW1NS, A Competitiveness Playbook For Sustaining Arizona’s Economic Momentum
PHOENIX, AZ (March 17, 2026) — As states across the country compete aggressively for talent, investment, and jobs, the Arizona Chamber Foundation and Arizona Commerce Authority today unveiled ArizonaW1NS a comprehensive competitiveness playbook designed to help Arizona sustain economic growth, strengthen its advantages, and expand opportunity statewide over the next decade.
Picard Medical / SynCardia Highlight Total Artificial Heart on BTV Program Airing on FOX Business News
Segment showcases SynCardia Total Artificial Heart supporting patients with advanced heart failure and next-generation development programsContinue reading
NSF-supported researchers expand storage capabilities of DNA
Researchers at Arizona State University’s Biodesign Institute and their collaborators have made a breakthrough in addressing this issue and taken a step that could enable DNA to serve as a building block for next-generation electronics. In a new study, a team demonstrated that by precisely controlling how metal ions bind within a DNA molecule, DNA can function as a fully electronic, chip-integrated memory system that is directly compatible with conventional electronics.
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
- Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix.
- NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the predicted SLN positivity rate is less than 5%. This report shows that patients with a less than 5% predicted risk of SLN positivity by the DecisionDx-Melanoma test had an actual SLN positivity rate of just 2.6%, and only 1.4% in patients with T1b–T2a tumors specifically, again confirming the clinically actionable performance of DecisionDx-Melanoma.
University of Arizona remembers former President Eugene G. Sander
Former University of Arizona President Eugene G. Sander passed away Feb. 22. He was 90.Continue reading
FDA Permits NuvOx Therapeutics to Initiate Phase II REBORN Trial of NanO2 in Recurrent High-Grade Glioma
Tucson, AZ –March 4, 2026, NuvOx Therapeutics, Inc. (“NuvOx”) today announced that the U.S. Food and Drug Administration (FDA) has authorized NuvOx to proceed with a new Phase II clinical trial evaluating NuvOx’s product candidate NanO2 (the active pharmaceutical ingredient of which is dodecafluoropentane) for the treatment of recurrent high-grade gliomas.Continue reading
Cinova Medical Acquires Elastomer Technologies, Inc.
Cinova Medical announced the acquisition of Elastomer Technologies, Inc. (ETI), a Southern California–based custom molder of liquid silicone rubber (LSR) and high-consistency gum rubbers serving the medical device and life sciences industries. ETI will continue operating from its current facility while Cinova Medical completes the expansion of a new Class 8 cleanroom dedicated to silicone molding. Upon completion, ETI’s manufacturing operations will be integrated into Cinova’s expanded production footprint. Headquartered in Phoenix, AZ, Cinova Medical is a vertically integrated contract manufacturer of precision-engineered, high-quality injection-molded and machined components, as well as complex Class II finished (sterile) medical devices.Continue reading